about
Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity.Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation.CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation.Omenn syndrome associated with a functional reversion due to a somatic second-site mutation in CARD11 deficiency.Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production.B cell survival, surface BCR and BAFFR expression, CD74 metabolism, and CD8- dendritic cells require the intramembrane endopeptidase SPPL2A.IgD attenuates the IgM-induced anergy response in transitional and mature B cells.Ndfip1 mediates peripheral tolerance to self and exogenous antigen by inducing cell cycle exit in responding CD4+ T cells.Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance.Systems-guided forward genetic screen reveals a critical role of the replication stress response protein ETAA1 in T cell clonal expansion.Inhibiting TLR9 and other UNC93B1-dependent TLRs paradoxically increases accumulation of MYD88L265P plasmablasts in vivo.Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation.Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM.Erratum: Phosphorylation and linear ubiquitin direct A20 inhibition of inflammationDistinctive roles of Fyn and Lyn in IgD- and IgM-mediated signalingCARD11 is dispensable for homeostatic responses and suppressive activity of peripherally induced FOXP3 + regulatory T cellsReduction of atherosclerosis despite hypercholesterolemia in lyn-deficient mice fed a high-fat dietOncogenic MYD88 mutation drives Toll pathway to lymphomaDenisovan, modern human and mouse TNFAIP3 alleles tune A20 phosphorylation and immunity
P50
Q33835200-2867E0D9-76C4-46AE-9A86-5411AE599E06Q33978723-B68CA425-6C1B-4497-A124-3EECB464381CQ34501441-138CBB64-57CA-4FA9-A7D0-AB6DA7168C4CQ36303058-786A17B8-5297-458B-AFDE-C67B52D6FAA1Q36340857-E5B5E22A-297E-4981-9413-2BC590B010F8Q36547677-E25C0698-73D4-4A19-84E6-D3AE5333703DQ37414331-680F2FAC-CE13-4A01-9158-647C10887F43Q37587748-F1CDC48F-A46C-4D54-9D57-7BC684E33515Q37630211-0A834B6E-D03A-42E4-9D25-869BEF35DA3CQ40162620-37130702-C95B-48D4-9494-ABD36A1B3E8AQ41168768-DE8D9BFE-460D-45A7-BFBA-E59E3E5862A5Q41791638-785A3E6D-B166-4ADB-8E50-95B98FAD785CQ48136905-D5B8FD24-FB25-44D8-BE9D-CCBA2527060AQ57088029-17BC6A15-B82D-4434-A6A0-D237B23EA90BQ58008762-3E65517C-965B-4AFB-BE06-F7B1B7411C6AQ67531729-F74CABC9-ABC3-408A-A3E9-6DF47FDD3819Q73418979-30D60AA3-886E-473F-982A-419E93A36FD1Q83965098-DC63A8B4-A06B-40CB-9D0F-23808C3FF804Q90168589-9595BD6C-6CBA-474A-AB81-90489C949484
P50
description
researcher, ORCID id # 0000-0002-7381-9450
@en
wetenschapper
@nl
name
Keisuke Horikawa
@ast
Keisuke Horikawa
@en
Keisuke Horikawa
@es
Keisuke Horikawa
@nl
type
label
Keisuke Horikawa
@ast
Keisuke Horikawa
@en
Keisuke Horikawa
@es
Keisuke Horikawa
@nl
prefLabel
Keisuke Horikawa
@ast
Keisuke Horikawa
@en
Keisuke Horikawa
@es
Keisuke Horikawa
@nl
P106
P1153
7102628941
P31
P496
0000-0002-7381-9450